Patard J J, Chopin D K
Ann Urol (Paris). 1993;27(1):24-30.
Local immunotherapy with BCG was first described by Zbar in an experimental model. The clinical use of BCG in human bladder carcinoma was proposed by Morales in 1976. Since then randomised studies have confirmed the value of BCG against recurrence and progression in superficial transitional cell carcinoma of the bladder (Lamm, Herr). However the optimal protocol has not been defined and the mode of action of BCG remains obscure. In this paper, the authors review the clinical results of BCG and its complications then focus on recent immunological data concerning its mode of action. Finally a practical protocol is proposed.
卡介苗局部免疫疗法最早由兹巴尔在一个实验模型中进行了描述。1976年，莫拉莱斯提出了卡介苗在人类膀胱癌中的临床应用。从那时起，随机研究证实了卡介苗对膀胱浅表性移行细胞癌复发和进展的治疗价值（拉姆、赫尔）。然而，最佳方案尚未确定，卡介苗的作用方式仍不明确。在本文中，作者回顾了卡介苗的临床效果及其并发症，然后重点关注了有关其作用方式的最新免疫学数据。最后提出了一个实用方案。
